Dosimetric evidences of 131I-MIBG treatment in High Risk Neuroblastoma in VERITAS protocol

被引：0
|
作者：
Saletti, P. [1 ]
Olianti, C. [1 ]
Tondo, A. [2 ]
Simontacchi, G. [1 ]
Belli, G. [1 ]
机构：
[1] AOU Careggi, Florence, Italy
[2] AOU Meyer, Florence, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2018年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-702
引用
收藏
页码：S225 / S225
页数：1
相关论文
共 50 条
  • [31] Upfront consolidation treatment with 131I-mIbG followed by myeloablative chemotherapy and hematopoietic stem cell transplantation in high-risk neuroblastoma
    Feng, Jianhua
    Cheng, Frankie W. T.
    Leung, Alex W. K.
    Lee, Vincent
    Yeung, Eva W. M.
    Lam, Hoi Ching
    Cheung, Jeanny
    Lam, Grace K. S.
    Chow, Terry T. W.
    Yan, Carol L. S.
    Li, Chi Kong
    PEDIATRIC INVESTIGATION, 2020, 4 (03) : 168 - 177
  • [32] CLINICAL IMPACT OF HIGH-DOSE 131I-MIBG THERAPY ON PATIENTS WITH NEWLY DIAGNOSED HIGH-RISK NEUROBLASTOMA
    Kuroda, Rie
    Nishimura, Ryosei
    Araki, Raita
    Takenaka, Mika
    Sakai, Yuta
    Noguchi, Kazuhiro
    Fujiki, Toshihiro
    Ikawa, Yasuhiro
    Wada, Taizo
    PEDIATRIC BLOOD & CANCER, 2024, 71 : S14 - S15
  • [33] Adjuvant use of 131I-MIBG in phaeochromocytoma and paraganglioma at high risk of malignancy
    Rutherford, M. A.
    Rankin, A. J.
    Yates, T. M.
    Reed, N. S.
    Perry, C. G.
    Freel, E. M.
    SCOTTISH MEDICAL JOURNAL, 2013, 58 (01) : E61 - E61
  • [34] Dosimetric advantage of combining 131I-MIBG and 90Y-DOTATOC
    Bushnell, David
    Madsen, Mark
    O'Dorisio, Tom
    Menda, Yusuf
    Schmitt, Beth
    O'Dorisio, Sue
    REGULATORY PEPTIDES, 2010, 164 (01) : 11 - 11
  • [35] Anatomic patterns of relapse and progression following treatment with 131I-MIBG in relapsed or refractory neuroblastoma
    Ben Kenan, Rotem Fishel
    Polishchuk, Alexei L.
    Hawkins, Randall A.
    Braunstein, Steve E.
    Matthay, Katherine K.
    DuBois, Steven G.
    Haas-Kogan, Daphne A.
    PEDIATRIC BLOOD & CANCER, 2022, 69 (02)
  • [36] THE ROLE OF 131I-METAIODOBENZYLGUANIDINE (131I-MIBG) THERAPY IN UNRESECTABLE AND COMPROMISING LOCALIZED NEUROBLASTOMA
    Schoot, Reineke
    Bleeker, Gitta
    Heij, Hugo
    van Eck, Berthe
    Caron, Huib
    de Kraker, Jan
    PEDIATRIC BLOOD & CANCER, 2009, 53 (05) : 807 - 808
  • [37] Radiation exposure in nurses during care of 131I-MIBG therapy for pediatric patients with high-risk neuroblastoma
    Yuka Taniguchi
    Hiroshi Wakabayashi
    Anri Inaki
    Daiki Kayano
    Masako Yamada
    Seigo Kinuya
    Annals of Nuclear Medicine, 2020, 34 : 441 - 447
  • [38] Dosimetry for fractionated 131I-mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results
    Buckley, S.
    Flux, G.
    Gaze, M.
    Chittenden, S.
    Partridge, M.
    Lancaster, D.
    Pearson, A.
    Saran, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S339 - S339
  • [39] Dosimetry for fractionated 131I-mIBG therapies in patients with primary resistant high-risk neuroblastoma:: Preliminary results
    Buckley, Susan E.
    Saran, Frank H.
    Gaze, Mark N.
    Chittenden, Sarah
    Partridge, Mike
    Lancaster, Donna
    Pearson, Andrew
    Flux, Glenn D.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2007, 22 (01) : 105 - 112
  • [40] Dosimetry-Based Tandem High-Dose 131I-MIBG Therapy For Paediatric Patients With High Risk Neuroblastoma
    Longo, M.
    Cassano, B.
    Genovese, E.
    Donatiello, S.
    Villani, M.
    Pizzoferro, M.
    Garganese, M.
    Serra, A.
    Castellano, A.
    Cannata, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S224 - S225
12345